140 related articles for article (PubMed ID: 23317527)
1. Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies.
Yasuda T; Suzuki R; Ishikawa Y; Terakura S; Inamoto Y; Yanada M; Nagai H; Ozawa Y; Ozeki K; Atsuta Y; Emi N; Naoe T
Int J Infect Dis; 2013 Jun; 17(6):e385-90. PubMed ID: 23317527
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.
Nakagawa Y; Suzuki K; Ohta K; Hino M; Ohyashiki K; Kanamaru A; Tamura K; Urabe A; Masaoka T;
J Infect Chemother; 2013 Feb; 19(1):103-11. PubMed ID: 22948387
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
4. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
5. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
[TBL] [Abstract][Full Text] [Related]
6. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
[TBL] [Abstract][Full Text] [Related]
7. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
[TBL] [Abstract][Full Text] [Related]
9. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial.
Engervall P; Kalin M; Dornbusch K; Björkholm M
J Chemother; 1999 Aug; 11(4):278-86. PubMed ID: 10465130
[TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
[TBL] [Abstract][Full Text] [Related]
11. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
[TBL] [Abstract][Full Text] [Related]
12. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients.
Sarashina T; Kobayashi R; Yoshida M; Toriumi N; Suzuki D; Sano H; Azuma H
Pediatr Blood Cancer; 2014 Nov; 61(11):1992-5. PubMed ID: 25130289
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intravenous ciprofloxacin in patients with febrile neutropenia refractory to initial therapy.
Matsuoka H; Tsukamoto A; Shirahashi A; Koga S; Suzushima H; Shibata K; Uozumi K; Yamashita K; Okamura S; Kawano F; Tamura K;
Leuk Lymphoma; 2006 Aug; 47(8):1618-23. PubMed ID: 16966275
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Chong Y; Shimoda S; Yakushiji H; Ito Y; Miyamoto T; Kamimura T; Shimono N; Akashi K
PLoS One; 2013; 8(1):e54190. PubMed ID: 23372683
[TBL] [Abstract][Full Text] [Related]
16. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin.
Cornely OA; Bethe U; Seifert H; Breuer K; Schütt-Gerowitt H; Salzberger B; Schrappe M; Fätkenheuer G
Ann Hematol; 2002 Jan; 81(1):37-43. PubMed ID: 11807634
[TBL] [Abstract][Full Text] [Related]
17. [Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward].
Shichmanter R; Miller EB; Shtalrid M; Landau Z
Harefuah; 2010 Dec; 149(12):765-8, 813, 812. PubMed ID: 21916097
[TBL] [Abstract][Full Text] [Related]
18. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
[TBL] [Abstract][Full Text] [Related]
20. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
